EGFR and non-small cell lung carcinoma: Building on the dual-targeting approach of the PD-L1 and VEGF pathways, the HARMONi-A trial evaluated ivonescimab, a bispecific antibody against PD-1 and VEGF, combined with chemotherapy, and demonstrated that dual inhibition can significantly improve PFS in EGFR-mutant NSCLC after prior TKI therapy.